Personalized medicines potential grows. But what signals real progress?

Posted: February 24, 2015 at 7:41 am

This post is sponsored by the MidAmerica Healthcare Venture Forum.

The table is set for jaw-dropping growth in the genomics/personalized medicine/precision medicine space. Pick your favorite news item. Is it the presidents new plan? The big investments out of JP Morgan? Or, most recently, the breakthrough decision by the FDA around 23andMe and other genetic testing kits?

Its not about whether personalized medicine has arrived. Its here. Now its about not getting lost in the hype and focusing on what matters.

Thats why weve assembled a strong cast of clinicians and innovators at the MidAmerica Healthcare Venture Forum on March 10-11 in Chicago who will keep us on track and explain how to maximize the potential of personalized medicine. MedCitys Meghana Keshavan will lead a discussion exploring not only what the next milestones are for the industry but also where the biggest opportunities are and what areas of personalized medicine need the most support.

Join us in Chicago and youll hear from the following panelists:

New funding and fresh attention bring new opportunities. The worst-case scenario for precision medicine is for investors, entrepreneurs and other healthcare leaders to squander it by getting lost amidst the hype and euphoria.

Our panel at the MidAmerica Healthcare Venture Forum will help keep everyone on track by sharing their hands-on knowledge on what it will take to deliver real success in personalized medicine. I hope you can join us March 10-11 in Chicago to participate in the discussion.

[Photo from Flickr user Craig Cloutier]

Get our daily newsletter or follow us.

Read more:
Personalized medicines potential grows. But what signals real progress?

Comments are closed.